503 related articles for article (PubMed ID: 30228206)
1. Stromal Cell PD-L1 Inhibits CD8
O'Malley G; Treacy O; Lynch K; Naicker SD; Leonard NA; Lohan P; Dunne PD; Ritter T; Egan LJ; Ryan AE
Cancer Immunol Res; 2018 Nov; 6(11):1426-1441. PubMed ID: 30228206
[TBL] [Abstract][Full Text] [Related]
2. MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells.
Zheng Z; Sun R; Zhao HJ; Fu D; Zhong HJ; Weng XQ; Qu B; Zhao Y; Wang L; Zhao WL
Mol Cancer; 2019 Mar; 18(1):54. PubMed ID: 30925928
[TBL] [Abstract][Full Text] [Related]
3. Stromal PD-1/PD-L1 Expression Predicts Outcome in Colon Cancer Patients.
Wyss J; Dislich B; Koelzer VH; Galván JA; Dawson H; Hädrich M; Inderbitzin D; Lugli A; Zlobec I; Berger MD
Clin Colorectal Cancer; 2019 Mar; 18(1):e20-e38. PubMed ID: 30389315
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of MDM2 Promotes Antitumor Responses in p53 Wild-Type Cancer Cells through Their Interaction with the Immune and Stromal Microenvironment.
Wang HQ; Mulford IJ; Sharp F; Liang J; Kurtulus S; Trabucco G; Quinn DS; Longmire TA; Patel N; Patil R; Shirley MD; Chen Y; Wang H; Ruddy DA; Fabre C; Williams JA; Hammerman PS; Mataraza J; Platzer B; Halilovic E
Cancer Res; 2021 Jun; 81(11):3079-3091. PubMed ID: 33504557
[TBL] [Abstract][Full Text] [Related]
5. Farnesoid X Receptor Constructs an Immunosuppressive Microenvironment and Sensitizes FXR
You W; Li L; Sun D; Liu X; Xia Z; Xue S; Chen B; Qin H; Ai J; Jiang H
Cancer Immunol Res; 2019 Jun; 7(6):990-1000. PubMed ID: 30975694
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic herpes simplex virus HF10 (canerpaturev) promotes accumulation of CD8
Eissa IR; Mukoyama N; Abdelmoneim M; Naoe Y; Matsumura S; Bustos-Villalobos I; Ichinose T; Miyajima N; Morimoto D; Tanaka M; Fujimoto Y; Sone M; Kodera Y; Kasuya H
Int J Cancer; 2021 Jul; 149(1):214-227. PubMed ID: 33687756
[TBL] [Abstract][Full Text] [Related]
7. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
8. PD-L1+ dendritic cells in the tumor microenvironment correlate with good prognosis and CD8+ T cell infiltration in colon cancer.
Miller TJ; Anyaegbu CC; Lee-Pullen TF; Spalding LJ; Platell CF; McCoy MJ
Cancer Sci; 2021 Mar; 112(3):1173-1183. PubMed ID: 33345422
[TBL] [Abstract][Full Text] [Related]
9. Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells.
Le Flahec G; Badic B; Guibourg B; Doucet L; Bail JP; Marcorelles P; Schick U; Uguen A
Hum Pathol; 2018 Feb; 72():135-143. PubMed ID: 29208565
[TBL] [Abstract][Full Text] [Related]
10. Infiltration of CD8 T Cells and Expression of PD-1 and PD-L1 in Synovial Sarcoma.
Nowicki TS; Akiyama R; Huang RR; Shintaku IP; Wang X; Tumeh PC; Singh A; Chmielowski B; Denny C; Federman N; Ribas A
Cancer Immunol Res; 2017 Feb; 5(2):118-126. PubMed ID: 28039162
[TBL] [Abstract][Full Text] [Related]
11. Transforming growth factor beta orchestrates PD-L1 enrichment in tumor-derived exosomes and mediates CD8 T-cell dysfunction regulating early phosphorylation of TCR signalome in breast cancer.
Chatterjee S; Chatterjee A; Jana S; Dey S; Roy H; Das MK; Alam J; Adhikary A; Chowdhury A; Biswas A; Manna D; Bhattacharyya A
Carcinogenesis; 2021 Feb; 42(1):38-47. PubMed ID: 32832992
[TBL] [Abstract][Full Text] [Related]
12. PRMT5 Inhibition Promotes PD-L1 Expression and Immuno-Resistance in Lung Cancer.
Hu R; Zhou B; Chen Z; Chen S; Chen N; Shen L; Xiao H; Zheng Y
Front Immunol; 2021; 12():722188. PubMed ID: 35111150
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy.
Knudson KM; Hicks KC; Alter S; Schlom J; Gameiro SR
J Immunother Cancer; 2019 Mar; 7(1):82. PubMed ID: 30898149
[TBL] [Abstract][Full Text] [Related]
14. PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression.
Jiao S; Xia W; Yamaguchi H; Wei Y; Chen MK; Hsu JM; Hsu JL; Yu WH; Du Y; Lee HH; Li CW; Chou CK; Lim SO; Chang SS; Litton J; Arun B; Hortobagyi GN; Hung MC
Clin Cancer Res; 2017 Jul; 23(14):3711-3720. PubMed ID: 28167507
[No Abstract] [Full Text] [Related]
15. Romidepsin (FK228) regulates the expression of the immune checkpoint ligand PD-L1 and suppresses cellular immune functions in colon cancer.
Shi Y; Fu Y; Zhang X; Zhao G; Yao Y; Guo Y; Ma G; Bai S; Li H
Cancer Immunol Immunother; 2021 Jan; 70(1):61-73. PubMed ID: 32632663
[TBL] [Abstract][Full Text] [Related]
16. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.
Tsukamoto H; Fujieda K; Miyashita A; Fukushima S; Ikeda T; Kubo Y; Senju S; Ihn H; Nishimura Y; Oshiumi H
Cancer Res; 2018 Sep; 78(17):5011-5022. PubMed ID: 29967259
[TBL] [Abstract][Full Text] [Related]
17. Control of PD-L1 expression in CLL-cells by stromal triggering of the Notch-c-Myc-EZH2 oncogenic signaling axis.
Böttcher M; Bruns H; Völkl S; Lu J; Chartomatsidou E; Papakonstantinou N; Mentz K; Büttner-Herold M; Zenz T; Herling M; Huber W; Ghia P; Stamatopoulos K; Mackensen A; Mougiakakos D
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33931470
[TBL] [Abstract][Full Text] [Related]
18. Indirect Impact of PD-1/PD-L1 Blockade on a Murine Model of NK Cell Exhaustion.
Alvarez M; Simonetta F; Baker J; Morrison AR; Wenokur AS; Pierini A; Berraondo P; Negrin RS
Front Immunol; 2020; 11():7. PubMed ID: 32117218
[TBL] [Abstract][Full Text] [Related]
19. Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma.
Görgün G; Samur MK; Cowens KB; Paula S; Bianchi G; Anderson JE; White RE; Singh A; Ohguchi H; Suzuki R; Kikuchi S; Harada T; Hideshima T; Tai YT; Laubach JP; Raje N; Magrangeas F; Minvielle S; Avet-Loiseau H; Munshi NC; Dorfman DM; Richardson PG; Anderson KC
Clin Cancer Res; 2015 Oct; 21(20):4607-18. PubMed ID: 25979485
[TBL] [Abstract][Full Text] [Related]
20. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]